Mydayis: Generic Composition
Mydayis is an extended-release formulation containing mixed amphetamine salts, specifically equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate, resulting in a 3:1 ratio of dextro- to levo-amphetamine base equivalent 1.
Specific Composition by Strength
Each Mydayis capsule contains the following four amphetamine salts in equal proportions:
- Dextroamphetamine saccharate
- Amphetamine aspartate monohydrate
- Dextroamphetamine sulfate
- Amphetamine sulfate
Available strengths include 12.5 mg, 25 mg, 37.5 mg, and 50 mg capsules. For example, a 25 mg capsule contains 6.25 mg of each of the four salts, totaling 25 mg of mixed amphetamine salts, which equals 15.6 mg amphetamine base equivalent 1.
Unique Delivery System
Mydayis employs a triple-bead extended-release system containing:
- One immediate-release bead component
- Two different delayed-release (DR) bead types that release amphetamine at different pH levels (pH 5.5 and pH 7.0)
This tri-phasic release mechanism provides extended duration of action, with peak plasma concentrations occurring at approximately 7-10 hours in pediatric patients and 8 hours in adults 1.
Clinical Context
As a CNS stimulant, amphetamines are first-line pharmacotherapy for ADHD 2. The mechanism involves blocking reuptake of norepinephrine and dopamine into presynaptic neurons while increasing release of these monoamines into the extraneuronal space 1. The 3:1 dextro- to levo-amphetamine ratio distinguishes this formulation from pure dextroamphetamine products and allows for differentiation in drug testing scenarios 3.